Skip to content
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
  • Language
  • +91 11 4925 6000
  • Request information
  • +91 11 4925 6000
  • Part of brands: |
IndiaIndia
  • Part of brands: |
  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS+ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • ALICE
      • Endometrio
      • Family POC
    • Patients
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS + ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • Family POC
      • ALICE
      • Endometrio
  • Diagnostic
  • About us
    • Igenomix Research
    • About Igenomix
  • ACADEMY
Genomics Precision Diagnostic > Neurology Precision Panel > Spinal Muscular Atrophies Precision Panel

Spinal Muscular Atrophies Precision Panel

Spinal Muscular Atrophies (SMAs) are a group of autosomal recessive inherited disorders characterized by progressive weakness of the lower motor neurons, manifesting as muscle weakness, atrophy and paralysis. 
Overview
Indication
Clinical Utility
Genes & Diseases
Methodology
References

Overview

  • Spinal Muscular Atrophies (SMAs) are a group of autosomal recessive inherited disorders characterized by progressive weakness of the lower motor neurons, manifesting as muscle weakness, atrophy and paralysis. It typically presents during infancy or early childhood and the severity of the disease correlates with the age of onset. The clinical and genetic phenotypes incorporate a broad spectrum that is differentiated according to the age of onset, pattern of muscle involvement, and inheritance pattern. There are four types of spinal muscular atrophies, described based on age when accompanying clinical features appear. Type 1 SMA (Werdnig-Hoffman disease) is associated with death within the first two years of life usually due to respiratory failure or aspiration pneumonia.   
  • The Igenomix Spinal Muscular Atrophies Precision Panel  can serve as an accurate diagnostic tool ultimately leading to a better management and prognosis of the disease. It provides a comprehensive analysis of the genes involved in this disease using next-generation sequencing (NGS) to fully understand the spectrum of relevant genes involved.  

Indication

  • The Igenomix Spinal Muscular Atrophies Precision Panel is indicated in patients with a clinical suspicion or diagnosis of Spinal Muscular Atrophy presenting with the following manifestations: 
    • Symmetric muscle weakness and hypotonia 
    • Limb and joint deformities 
    • Fasciculations of the tongue 
    • Absent deep tendon reflexes 
    • Flaccid “frog like” posture 
    • Restrictive respiratory insufficiency 

Clinical Utility

The clinical utility of this panel is: 

    • The genetic and molecular diagnosis for an accurate clinical diagnosis of a symptomatic patient.  
    • Early initiation of treatment with a multidisciplinary team in the form of neuroprotective approaches to support muscle strength and function, orthopaedic intervention, appropriate physical therapy and rehabilitation, and prevention of complications. 
    • Initiation of novel therapeutic strategies including measures to selectively address survival motor neuron protein deficiency with SMN1 gene replacement or modulation of SMN2 encoded protein levels.  
    • Risk assessment and genetic counselling of asymptomatic family members according to the mode of inheritance.
    • Improvement of delineation of genotype-phenotype correlation.  

Genes & Diseases

Methodology

References

See scientific referrals

Farrar, M. A., & Kiernan, M. C. (2015). The Genetics of Spinal Muscular Atrophy: Progress and Challenges. Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 12(2), 290–302. https://doi.org/10.1007/s13311-014-0314-x 

Arnold, E. S., & Fischbeck, K. H. (2018). Spinal muscular atrophy. Handbook of clinical neurology, 148, 591–601. https://doi.org/10.1016/B978-0-444-64076-5.00038-7 

Arnold, W. D., Kassar, D., & Kissel, J. T. (2015). Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle & nerve, 51(2), 157–167. https://doi.org/10.1002/mus.24497 

Kariyawasam, D., Carey, K. A., Jones, K. J., & Farrar, M. A. (2018). New and developing therapies in spinal muscular atrophy. Paediatric respiratory reviews, 28, 3–10. https://doi.org/10.1016/j.prrv.2018.03.003 

Lunn, M. R., & Wang, C. H. (2008). Spinal muscular atrophy. The Lancet, 371(9630), 2120-2133. doi:10.1016/s0140-6736(08)60921-6 

Frugier, T., Nicole, S., Cifuentes-Diaz, C., & Melki, J. (2002). The molecular bases of spinal muscular atrophy. Current Opinion in Genetics & Development, 12(3), 294-298. doi:10.1016/s0959-437x(02)00301-5 

descargar

Detail description

Download



IGENOMIX_PartOfVitrolifeGroup_black

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

OUR SERVICES

Genetic solutions
Learn about genetics
How to send a sample

ABOUT US

About Igenomix
Contact
Quality
Work with us

FOLLOW IGENOMIX

Blog: Path to fertility

  +91 11 4925 6000
  Write us
  • Brazil
  • Canada
  • Europe
  • India
  • Italy
  • Japan
  • Korea
  • Latam
  • Spain
  • Taiwan
  • The Middle East
  • Turkey
  • United Kingdom
  • United States
Language

[2024] © Igenomix Privacy policy Quality policy Legal note Cookies policy




  • We guide you
    • Fertility
    • Inherited diseases
    • Worry-free pregnancy
  • Reproductive Health
    • Specialists
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS+ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • ALICE
      • Endometrio
      • Family POC
    • Patients
      • SAT
      • CGT
      • PGT-A
      • PGT-M
      • PGS + ERA Synchrony
      • Embrace
      • ERA
      • EMMA
      • Family POC
      • ALICE
      • Endometrio
  • Diagnostic
  • About us
    • Igenomix Research
    • About Igenomix
  • ACADEMY
  • Language
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT